| Basics |
Amgen Inc.
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$152.7B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.39 | 0.99%
|
| Avg Daily Range (30 D): |
$2.70 | 0.92%
|
| Avg Daily Range (90 D): |
$3.42 | 1.19%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.81M |
| Avg Daily Volume (30 D): |
1.48M |
| Avg Daily Volume (90 D): |
1.87M |
| Trade Size |
| Avg Trade Size (Sh.): |
133 |
| Avg Trade Size (Sh.) (30 D): |
34 |
| Avg Trade Size (Sh.) (90 D): |
37 |
| Institutional Trades |
| Total Inst.Trades: |
113,845 |
| Avg Inst. Trade: |
$6.25M |
| Avg Inst. Trade (30 D): |
$31.67M |
| Avg Inst. Trade (90 D): |
$29.29M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
20 |
| Market Closing Trades |
| Avg Closing Trade: |
$64.35M |
| Avg Closing Trade (30 D): |
$123.49M |
| Avg Closing Trade (90 D): |
$131.85M |
| Avg Closing Volume: |
386.75K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$2.66
|
$3.22
|
|
Diluted EPS
|
|
$2.65
|
$3.2
|
|
Revenue
|
$
|
$ 9.18B
|
$ 8.15B
|
|
Gross Profit
|
$
|
$ 6.17B
|
$ 5.18B
|
|
Net Income / Loss
|
$
|
$ 1.43B
|
$ 1.73B
|
|
Operating Income / Loss
|
$
|
$ 2.66B
|
$ 1.18B
|
|
Cost of Revenue
|
$
|
$ 3.01B
|
$ 2.97B
|
|
Net Cash Flow
|
$
|
$ -782M
|
$ -3163M
|
|
PE Ratio
|
|
|
|
|
|
|
